COVID-19 has produced some unusual claims from companies at the speculative end of the markets. On Tuesday, biotech Starpharma pitched institutional investors at the Macquarie Australia Conference the efficacy of its SPL1703 gel ingredient as an antiviral agent in treating the coronavirus. There are claims now that lab tests of SPL7013 performed better than Gilead’s remdesivir in preventing SARS-CoV-2 viral infection. Starpharma to develop COVID-19 treatment Victoria, Australia-based StarPharma (OTCQX:SPHRY), seller of a lineup of women’s health products under the VivaGel brand, says the active ingredient, SPL7013, showed “significant activity” against SARS-CoV-2 in labRead More